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Abstract Amikacin plays a key role in the treatment of
severe hospital-acquired infections with Gram-negative
bacteria. Therapeutic use of amikacin is challenged by high
inter-individual variability (IIV) combined with a narrow
therapeutic spectrum. Pediatric patients represent a partic-
ularly fragile population where adequate dosing is crucial
yet challenging to achieve due significant IIV associated
with developmental processes and other factors. The cur-
rent review provides an overview of parametric population
pharmacokinetic analyses of amikacin in pediatric patients
and associated patient-specific determinants of IIV. We
searched PubMed for parametric population pharmacoki-
netic analyses of amikacin in pediatric patients. Informa-
tion on patient population, study design, pharmacokinetic
model characteristics, and identified patient-specific pre-
dictors of IIV was collected. Comparative analyses across
studies were conducted to characterize quantitative differ-
ences reported for different studies and patient populations.
Eight eligible publications were identified, of which six
analyses involved neonates up to 3 months of age and two
studies investigated older pediatric patients (age
2–17 years). Most commonly included covariates were
current body weight for both clearance and volume of
distribution, followed by age-related covariates on clear-
ance in neonatal studies (four of six models). Quantitative
comparisons of different models reported generally showed
similar developmental effects in neonatal populations. The
present review provides a comprehensive overview of
parametric population pharmacokinetic studies for amika-
cin. Future studies could address the knowledge gap of
patients between 3 months and 2 years of age. Further-
more, systematic studies of additional potential predictors
for IIV (e.g., sepsis, inflammatory markers, renal function
biomarkers) could be of relevance to address the significant
IIV remaining after inclusion of the most commonly
identified covariates.
Key Points
Optimal dosing of amikacin in pediatric patients is
challenging due to significant inter-individual
variability (IIV) associated with developmental
processes.
All analyses reported current body weight as a
predictor for IIV in clearance and volume of
distribution, while some analyses identified other
predictors including age-related covariates and
predictors of glomerular filtration rate.
Between the age of 3 months and 2 years, there is a
lack of studies that characterize the
pharmacokinetics of amikacin.
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1 Introduction
Amikacin is an aminoglycoside antibiotic primarily used
for the treatment of infections caused by aerobic Gram-
negative bacilli when first-line antibiotic treatment is
ineffective [1]. Amikacin has an important place in the
treatment of bacterial infections in pediatric patients. It is
the second most commonly used antibiotic in neonatal
intensive care units [2], primarily prescribed for the treat-
ment of neonatal sepsis, necrotizing enterocolitis, menin-
gitis, and empirical antibiotic therapy [3]. In addition,
amikacin has an important role in the treatment of acute
pulmonary exacerbations of cystic fibrosis patients [4, 5].
Therapeutic use of amikacin is challenged by high inter-
individual variability (IIV) combined with a narrow ther-
apeutic spectrum. Therapeutic drug monitoring (TDM)
therefore plays an important role in optimizing amikacin
dosing. A ratio of the maximum (peak) concentration
(Cmax) divided by the minimum inhibitory concentration
(MIC) of a given pathogen (peak/MIC) of at least 8–10 is
recommended for effective amikacin therapy, with target
trough concentrations (Ctrough) as low as possible [6].
However, TDM approaches can only be implemented some
time after treatment is started. Therefore, identification of
patient-specific predictors of IIV in clearance (CL) and
volume of distribution (Vd) in individual patients is crucial
to achieve effective and safe dose regimens as early as
possible.
Dose optimization in the pediatric population is partic-
ularly challenging. Several studies have demonstrated that
drug plasma CL and Vd are affected by developmental
processes beyond change in body size alone [7]. Similarly,
significant changes in body water and body fat occur dur-
ing pediatric development [7]. In addition, pathophysio-
logical states such as sepsis or burns may affect the
pharmacokinetics of amikacin and can introduce further
IIV [8].
Population pharmacokinetic modeling now has an
established role in identifying patient-specific predictors
that determine IIV and rationally deriving individualized
dose regimens [9]. Indeed, various population pharma-
cokinetic analyses of amikacin in the pediatric population
have been reported for different pediatric sub-populations.
The aim of this review is to identify, summarize, and
compare parametric population pharmacokinetic analyses
of amikacin in the pediatric population in order to identify
the most commonly identified predictors of IIV and
knowledge gaps that remain.
2 Methods
2.1 Search Strategy
The following PubMed search query was used to identify
relevant publications: (‘‘amikacin’’[title] OR
‘‘amikacine’’[title] OR ‘‘Amikin’’[title]) AND (‘‘popula-
tion pharmacokinetic*’’[tiab] OR ‘‘NONMEM’’[tiab] OR
‘‘WinNonMix’’[tiab] OR ‘‘*bugs’’[tiab] OR ‘‘SAAM’’[-
tiab] OR ‘‘*ADAPT’’[tiab] OR ‘‘monolix’’[tiab] OR
‘‘mixed effect’’[tiab] OR ‘‘population model*’’[tiab] OR
‘‘popPK’’[tiab] OR ‘‘pop PK’’[tiab] OR ‘‘NLME’’[tiab] OR
‘‘compartmental pharmacokinetic*’’[tiab] OR ‘‘pharma-
cokinetic* model*’’ [tiab]) AND (‘‘pediatric’’ [tiab] OR
‘‘paediatric’’ [tiab] OR ‘‘neonates’’[tiab]) AND (‘‘1900/01/
01’’[PDat] : ‘‘2016/12/31’’[PDat]) NOT (review[pt]) AND
(‘‘english’’[LA]) NOT (‘‘foal*’’[tiab] OR ‘‘mice’’[tiab] OR
‘‘rat*’’[tiab] OR ‘‘rabbit’’[tiab]). Additional studies were
identified from the reference lists of selected papers.
Publications were included if they described a para-
metric population pharmacokinetic analysis of amikacin in
pediatric patients (neonates, infants, children, or adoles-
cents). Studies that used non-compartmental or non-para-
metric approaches were not included.
2.2 Data Extraction
The following information was extracted for each of the
included publications: aim of the study, patient population,
key demographics and laboratory measurements, study
design characteristics related to drug treatment and sam-
pling design, data analysis software, structural and statis-
tical model parameter estimates, patient-specific covariates
predictive of IIV, and model evaluation strategy.
2.3 Comparison of Studies
Study and patient characteristics, pharmacokinetic param-
eters, identified covariates, and model analysis strategies
were summarized in tables. We quantitatively compared
differences in typical parameter estimates for CL and Vd
across reported models. We scaled the typical parameter
estimates and their associated distributions for IIV by
current body weight. For additional continuous covariates
present in some models we used the respective median
values reported in the study. For binary covariates
(ibuprofen/non-steroidal anti-inflammatory drug [NSAID]
use, ventilation, inotropes, small for gestational age [GA]),
we assumed these were not present. For a model that
included sex as covariate, we assumed males.
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3 Results
We identified a total of 16 studies, of which seven studies
were eligible and nine studies were excluded. Reasons for
exclusion were not using a parametric population analysis
[10–12], reporting of simulations alone [13], unable to
retrieve publication [14], lack of human subjects [15], and
application of an existing population pharmacokinetic
model [16–18]. One additional study was identified
through the selected papers [19]. Identified studies were
published between 1998 and 2016.
The population characteristics, study design, and model
analysis details of the included eight publications are pro-
vided in Tables 1, 2, and 3, respectively. Six of the
included publications studied neonates, and two publica-
tions studied children and adolescents, of which one stud-
ied pediatric burn patients [20] (Table 1).
As expected, all analyses aimed to characterize IIV in
amikacin pharmacokinetics and to identify predictors for
dosing. In addition, two analyses [21, 22] also proposed a
new dose schedule based on the developed model. Only
one publication [21] additionally explored the relation
between pharmacokinetics and treatment failure, allowing
the estimation of new amikacin target concentrations and
the development of an alternative dosing regimen.
Amikacin was administered as an intravenous infusion
in all cases except in one study [23] where an intravenous
bolus dose was used. Dose regimens studied ranged
Table 1 Overview of study population characteristics
Patients n (M/F) Age (y) GA PNA PMA Weight (kg) SCR (mg/dL) eGFR (mL/min/1.73 m2)a References
Neonates
874
(nr/nr)
30.5
[24–43]
2
[1–30]
nr 1.52
[0.39–4.78]
nr nr [22]b
80
(46/34)
28
[24–41]
9
[3–64]
29.43
[24.7–44]
1.03
[0.45–4.43]
0.66
[0.23–1.26]
nr [21]
205
(nr/nr)
28 [24–30] \ 3 nr 1.07± 0.34 nr nr [19]
715
(nr/nr)
nr \ 29 nr [24–43] nr [0.39–4.78] nr nr [24]
53
(30/23)
35.1± 3.6 3.1± 3.1 nr 2.1± 0.8c nr nr [23]
149
(86/63)
31.8
[24.3–41]
28
[1–86]
248
[175–360]
1.92
[0.50–4.65]
0.58
[0.19–2.50]
32.28
[5.87–121.5]
[25]
Infants/children/adolescents
Children
(burns)
70
(45/25)
4.5
[2–10]d
20
[13–49]d
nr nr [28]
Children/
adolescents
32
(20/12)
7 [2–14]d 22.9
[14.8–46.3]d
nr nr [28]
Infants/
children/
adolescents
(burns)
70
(45/25)
4.5
[0.6–17]
20
[8–90]
nr nr [20]
Values are expressed as median [range] or mean± standard deviation
eGFR estimated glomerular filtration rate, F female, GA gestational age, M male, nr not reported, PMA postmenstrual age, PNA postnatal age, SCR serum
creatinine
aeGFR from the Schwartz formula
bThe study of De Cock et al. [22], although modeled independently, was based on data from two previously published studies [19, 24]
cRefers to birth weight (kg)
dValues expressed as median (interquartile range)
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between 2.8–58.4 and 8–20 mg/kg per dose and dosing
intervals ranged between 8–48 and 6–24 h for neonates and
older pediatric patients, respectively (Table 2). All analy-
ses were retrospective and based on amikacin concentra-
tions generated during routine TDM. Of note, the study by
De Cock et al. [22], although modeled independently, was
based on clinical study data described in two previously
published analyses also included in this review [19, 24].
Study datasets generally consisted of sparsely sampled
data, i.e., after end of infusion (Cmax) and just before the
next drug administration (Ctrough). The majority of analyses
reported one-compartment models, with the exception of
two analyses in neonates [22, 25] and one analysis in
pediatric burn patients [20] (Table 3), where additional
opportunistic samples were available.
Table 2 Study design characteristics
Patients Drug treatment Samples References
Dose (mg/kg) Interval (h) Times n/patients Total
Neonates
nr [15.5–20] 24–42 P, T nr [2–nr] 2186 [22]
nr [15–18] 24–48 P, T nr [1–nr] 358 [21]
nr [15.5–20] 24–42 P, T nr [2–nr] 410 [19]
nr [15.5–20] 24–42 P, T nr [2–nr] 1862 [24]
nr [7.5–15]a 12–24 P, T 2 [2] 106 [23]
11.62 [2.8–58.4] 8–48 P, T 2–11 446 [25]
Infants/children/adolescents
Children (burns) 16 [13–20]b 8 P, T nr [1–nr] 282 [28]
Children/adolescents 15 [8–16]b 24 P, T nr [1–nr] 99 [28]
Infants/children/adolescents (burns) 16.4 ± 3.9 6–12 P, T nr [1–nr] 282 [20]
Values are expressed as median [range] or mean± standard deviation
nr not reported, P peak samples, T trough samples
aWith a previous loading dose of either 17.5 mg/kg or 10 mg
bExpressed as median [interquartile range]
Table 3 Modeling analyses characteristics
Patients Aimsa Number of
compartments
Model
evaluation
Software External
validationb
References
Neonates
1, 2 Two DP, IS, BO, EE NONMEM Yes (239) [22]
1, 2, 3 One DP, IS, BO NONMEM No [21]
1 One No NONMEM No [19]
1 One No NONMEM No [24]
1 One No NONMEM No [23]
1, 2 Two DP, IS, BO, EE NONMEM Yes (53) [25]
Infants/children/adolescents
Children (burns) 1, 2 One DP, IS, BO NONMEM No [28]
Children/adolescents 1, 2 One DP, IS, BO NONMEM No [28]
Infants/children/adolescents
(burns)
1 Two DP, BO NONMEM No [20]
BO bootstrap, DP diagnostic plots, EE external evaluation, IS internal simulation
aAims: (1) to characterize pharmacokinetics and identify predictors for dosing/pharmacokinetic parameters; (2) to propose a new dose schedule;
(3) to investigate pharmacodynamics
bNumber of individuals used for the external validation given in parentheses
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The identified mean population pharmacokinetic
parameter estimates and associated covariate models for
patient-specific predictors of IIV are summarized in
Table 4. Typical parameter estimates and associated IIV
for CL and central volume of distribution (Vc) scaled by
weight are shown in Fig. 1. The median values and range
of CL and Vc of amikacin in neonates were 0.037 L/h/kg
(0.026–0.056 L/h/kg) and 0.477 L/kg (0.334–0.574 L/kg),
and 0.120 L/h/kg (0.101–0.141 L/h/kg) and 0.277 L/kg
(0.239–0.324 L/kg) in non-neonatal populations. In gen-
eral, CL in neonates was lower than in the other pediatric
populations (Fig. 1).
For neonatal populations, covariates selected among the
different analyses were demographic factors including
weight (birth weight [BWT] and current weight [cWT]),
age (postnatal, postmenstrual, and postconceptional ages)
and sex, renal function parameters (serum creatinine and
estimated glomerular filtration rate [eGFR]), administration
of drugs (ibuprofen and use of inotropes), intrauterine
growth retardation (dichotomous variable), and positive
pressure artificial ventilation. All identified models incor-
porated cWT on Vc and CL, except the analysis by De
Cock et al. [22], which incorporated BWT instead of cWT
on CL (Table 5). For non-neonatal populations, the only
covariate included on both Vc and CL was cWT (Table 5).
Figure 2 shows the change in predicted CL in relation to
body weight.
The majority of analyses estimated IIV on CL and Vc.
De Cock et al. [22] only estimated IIV on CL. Two anal-
yses which identified two-compartmental pharmacokinetics
also estimated IIV on inter-compartmental CL (Q) in
neonates [25] and older pediatric patients [20]. In neonatal
studies, IIV on CL was significant and ranged substantially
from 4.6 to 34.93%. IIV in Vc ranged from 0.446 to 45.1%.
Similar variability was also seen in non-neonatal studies
for CL (24.5–54.9%) and Vc (10–24.9%). Only Illamola
et al. [25] reported eta shrinkage values of 17.9 and 42.4%
for CL and Vd, respectively.
Inter-occasion variability (IOV) in pharmacokinetic
parameters is of clinical importance as significant IOV
impacts the effectiveness of TDM strategies [26]. IOV was
not included in the models of the non-neonatal analyses.
For the neonatal analyses it was reportedly assessed in
three analyses [21, 24, 25] and was incorporated in only
one publication [24], with an IOV estimated for CL of
11.6%. Other analyses may potentially not have had suf-
ficient multiple occasions data to allow its estimation.
Residual variability, which can constitute intra-subject
variability but also errors due to bioanalytical methodol-
ogy, sample time recording, or model misspecifications,
ranged from a proportional error of 18–50% across anal-
yses, with an additive error ranging from 0.283 to 1.59 mg/
L in neonates, and from 0.499 to 1.80 mg/L in a non-
neonatal population.
Most analyses used standard pharmacokinetic model
evaluation diagnostic methods such as goodness-of-fit plots
and visual predictive checks [27]. Only two neonatal
studies [22, 25] performed an external evaluation using
pharmacokinetic data from a cohort of patients not used for
model development. Of note, the population pharmacoki-
netic analysis by De Cock et al. [22] finally incorporated
part of the data [21] used for the external evaluation to re-
estimate the parameters of the final model. Three studies
[19, 23, 24] did not report any details of model evaluation.
4 Discussion
This review summarizes eight population pharmacokinetic
analyses of amikacin in the pediatric population, the
majority of which were based on considerable study sizes
of[50 patients, thus allowing good identification of the
covariates with a significant effect on the final estimated
pharmacokinetic parameters. Only the analysis of non-
burned children and adolescents studied by Yu et al. [28]
had a lower sample size (n = 32). There was a large
overlap in the underlying study data used for the population
pharmacokinetic analysis by De Cock et al. [22] and the
analyses from Allegaert et al. [19, 24].
The use of sparse pharmacokinetic data derived from
TDM practice is very common in pharmacokinetic analy-
ses of neonatal populations due to the limitations of
implementing rich sampling strategies in this group of
patients (e.g., ethical challenges, blood volume). For this
reason, TDM data sometimes become a useful alternative
for pharmacokinetic studies. For instance, the limitations of
using such sparse pharmacokinetic data are made clear by
the general inability to identify two-compartmental phar-
macokinetic models. Potentially, more frequently identified
one-compartment models may lead to sub-optimal char-
acterization of early distribution kinetics and a less accu-
rate prediction of target peak coverage than with two-
compartment models.
Overall, there was a reasonable agreement in estimates
of amikacin pharmacokinetic parameters and identified
predictors for IIV. Clear developmental effects for CL were
identified across all analyses. The analysis by De Cock
et al. [22], which included the largest dataset of immature
preterm neonates, reported the lowest CL estimates. After
inclusion of covariates, IIV in CL still remained between
4.6 and 55%. Sherwin et al. [21] reported notably small
estimates for IIV in both CL and Vc compared with most
other analyses. These lower estimates could be associated
with the fact that most of the neonates included in the
pharmacokinetic analysis were extremely low-birth-weight
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infants (\1000 g) and extremely premature (GA
\28 weeks), therefore providing a possible bias in the
pharmacokinetic model. Vd values were typically larger in
neonates than in older pediatric individuals. This may be
explained by the fact that for highly water-soluble com-
pounds, such as amikacin, Vd values in neonates are usually
greater than in adults [29]. In general, reported values of
IIV in Vd and CL were quite similar, but with some
exceptions such as the study of Sherwin et al. [21], which
reported an IIV in Vd of 4.6 and 0.446% in CL. In this case,
and as stated in the limitations of the paper, the opportunity
to capture IIV was limited due to the great similarity of the
neonates included in the study (most of them extremely
low BWT and premature). Another example is the study of
Yu et al. [28], specifically the group of non-burned children
and adolescents, where IIV in Vd was not estimated but
fixed at 10%. Therefore, the reported IIV in Vd could be
falsely low, and thus the difference between IIV in Vd and
CL erroneous. Nonetheless, the magnitude of IIV in Vd and
CL is of great importance, especially in the context of
TDM, as it highlights the need to monitor Cmax and Ctrough,
respectively.
Some inherent limitations in the comparisons of CL and
Vd across studies exist based on scaling by current body
weight as there are significant differences in the additional
covariates present and associated parametrizations. The
parameters were scaled linearly, and additional covariates
that were present were not considered. In case of the study
by De Cock et al. [22] BWT was reported, which makes the
comparison with the other studies potentially less clear.
Nonetheless we believe this comparison is of relevance as
it suggests general agreement between studies in specific
pediatric patient populations.
The most commonly included predictors of IIV on CL
were cWT, age-related covariates (postnatal age [PNA],
postmenstrual age [PMA], postconceptional age [PCA]),
and predictors of glomerular filtration rate [GFR]. For Vc,
cWT was the most common covariate included as predic-
tor. All pediatric analyses included cWT for CL and Vc,
except the analysis by De Cock et al. [22], which incor-
porated BWT instead of cWT on CL. The introduction of
BWT instead of cWT was chosen by the authors to
potentially more accurately reflect the antenatal matura-
tion, while PNA, also introduced on CL, represents the
postnatal maturation. The relationship between body
weight and either CL or Vc was described by allometric
equations [30] in all analyses. In all non-neonatal and in
only two of the six neonatal analyses, a fixed allometric
power parameter value of 0.75 for CL and 1 for Vc were
assigned. These values were estimated in the remaining
four neonatal analyses.
Age descriptors included in the models were PCA [19],
PMA [21, 24], and PNA [22]. PCA and PMA, which are aT
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combination of GA and PNA, quantify both maturation
before and after birth, whilst PNA only quantifies
maturation after birth. The inclusion of one or other age
descriptor in the model could be influenced by which of
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Fig. 1 Typical parameter estimates for clearance and central volume, scaled by body weight. The error bars represent the 10th and 90th
percentile for inter-individual variability, if estimated. It should be noted that De Cock et al. [22] use birth weight and not current body weight
Table 5 Covariates tested and retained for total clearance and central volume of distribution for different models
Population Study Covariates tested Retained covariates in final model
Covariates * CL Covariates * Vc
Neonates
De Cock et al.
[22]
cWT, BWT, GA, PMA, PNA, SCR, IB,
PEB
BWT, PNA, IB cWT
Sherwin et al.
[21]
SEX, cWT, GA, PMA, PNA, SCR,
AP1, AP5, SEP
cWT, PMA cWT
Allegaert et al.
[19]
cWT, PCA, FNSAID, PEB, PEI, AP1,
AP10, PNC
cWT, PCA, FNSAID cWT
Allegaert et al.
[24]
cWT, PMA, PNA, SGA, SCR, DP, IB,
PBC, RS
cWT, PMA, SGA, SCR,
FINO, FVENT
cWT, PNA, FINO,
FVENT
Botha et al.
[23]
SEX, GA, PCA, PNA, SFGA, DR,
AP1, AP5
SEX, cWT cWT
Illamola et al.
[25]
SEX, GA, BWT, HT, eGFR, SCR,
PMA, PNA
cWT, CLCR cWT
Infants/children/adolescents
Children (burns) Yu et al. [28] AGE, SEX, cWT, HT, SCR, PBS, TEB cWT cWT
Children/adolescents Yu et al. [28] AGE, SEX, cWT, HT, SCR cWT cWT
Infants/children/
adolescents (burns)
Sherwin et al.
[20]
AGE, SEX, cWT, HT, SCR, PBS cWT cWT
AP1 Apgar score at minute 1, AP5 Apgar score at minute 5, AP10 Apgar score at minute 10, BWT birth weight, CL total clearance, cWT current
body weight, DP co-administration of dopamine, DR dosing regimen (once or twice per day), eGFR estimated glomerular filtration rate, FINO
scaling factor for the use of inotropes, FNSAIDs scaling factor for premature neonates given a non-steroidal anti-inflammatory drug, FVENT
scaling factor for the use of positive pressure artificial ventilation, GA gestational age, HT height, IB co-administration of ibuprofen, PBC
positive blood culture, PBS percentage of body surface burned, PCA postconceptional age, PEB prenatal exposure to betamethasone, PEI
prenatal exposure to indomethacin, PMA postmenstrual age, PNA postnatal age, PNC perinatal chorioamnionitis, RS respiratory support, SCR
serum creatinine, SEP sepsis, SEX gender, SFGA size for gestational age, SGA intrauterine growth retardation, TEB amount of time elapsed since
the burn injury, Vc central volume of distribution
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these covariates were tested. While three [21, 22, 25] of the
six neonatal analyses tested three different age descriptors
(GA, PMA, and PNA), the three remaining analyses only
tested one. Age descriptors are composite metrics that
include description of both changes in size and renal
function. As the majority of models included both cWT
and age descriptors, the function of age in such models can
thus be interpreted as a surrogate marker for renal function.
A limitation of such an approach may be cases where
patients have an atypical renal function for their respective
age.
Three [21, 22, 25] of the six neonatal studies evaluated
the potential use of predictors of GFR (e.g., serum crea-
tinine, eGFR) as predictors of IIV on CL instead of age,
with one analysis finally selecting eGFR as a final predictor
[25]. This has the advantage of being a more direct renal
function marker that is directly relevant for the renal CL of
amikacin, and which thereby may allow it to better handle
atypical patients. However, the use of serum creatinine
levels in neonates is still controversial due to the influence
of maternal creatinine levels and variations during the first
year of PNA [31], as well as the bioanalytical method used
for its quantification. In addition to predictors of GFR,
some analyses included indirect predictors that may affect
renal function, including the use of NSAIDs [19, 22] and
inotrope support [24]. Finally, burn injuries are known to
have significant effects on the pharmacokinetics of several
drugs [32–34]. Indeed, also for amikacin, Yu et al. [28]
reported increased CL and Vc values of 34.5 and 21.4%,
respectively, in a group of children with burn injuries
compared with a group of children without. Across all
analyses, the inclusion of potential predictors for IIV was
generally guided by data-driven decision making, i.e., by
goodness-of-fit metrics, except for decisions to include
fixed allometric scaling.
Residual variability is of great importance when the
developed models are used for TDM applications because
high additive and proportional errors may significantly
impact the uncertainty of predicted Ctrough and Cmax values,
respectively. For that reason, these values will dictate the
utility of the developed model to identify the optimal
schedule dosing regimen in clinical practice.
Only two population analyses also proposed optimized
model-based dosing regimens for neonates [21, 22, 25]
Fig. 2 Change in mean
population pharmacokinetic
model-predicted clearance in
relation to body weight, in
neonates and pediatric patients.
It should be noted that De Cock
et al. [22] use birth weight and
not current body weight
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(Table 6). The dosing guidelines proposed by Sherwin
et al. [21] are based on PMA, and those of De Cock et al.
[22] are based on combinations of PNA and cWT. In both
cases, the recommended dose intervals increase with the
immaturity of the neonates. However, based on the con-
siderable IIV of CL reported, amikacin dosing intervals can
differ significantly within the same group. For the devel-
opment of the proposed dosing regimens, both Sherwin
et al. [21] and De Cock et al. [22] adopted Cmax values
between 24 and 35 mg/L as the target value. However,
Sherwin et al. [21] additionally used the area under the
concentration–time curve from time zero to 24 h (AUC24)
(130–590 mg h/L), while De Cock et al. [22] used Ctrough
(1.5–3 mg/L). The dose regimen by De Cock et al. [22]
appeared to be derived without full consideration of IIV
since the authors note simulations were conducted ‘‘with
exclusion of the interindividual and residual variability’’.
However, it was the only recent proposed optimized dosing
regimen that was also successfully prospectively validated
[17] to improve target Ctrough and Cmax values in almost all
individuals.
In order to define rational dosing regimens, population
pharmacokinetic/pharmacodynamic studies in children are
needed. In this review, only one study explored pharma-
cokinetic/pharmacodynamic relationships on the basis of
individual pharmacokinetic parameter estimates, which
brings to light a lack of pharmacokinetic/pharmacody-
namic studies in pediatrics that needs to be urgently rec-
tified [9, 35]. The current overview of different published
population pharmacokinetic models for amikacin will
allow further pharmacokinetic/pharmacodynamic simula-
tion studies to calculate the target attainment for different
dose regimen across models, and particularly within dif-
ferent pediatric patient populations studied.
5 Conclusions
This review summarizes key analysis of the population
pharmacokinetics of amikacin. We summarized key pre-
dictors that can be considered for amikacin dose regimen
optimization, which include a combination of body weight
and age or renal function-based predictors. Population
pharmacokinetic studies of amikacin in non-neonatal
patients are, however, limited, and are non-existent for
most of the infant population (3 months to 2 years of age),
which represents an important knowledge gap as there is a
clear change in typical CL between these two age groups.
Furthermore, studies in specific patient groups where the
use of amikacin is of relevance (i.e., cystic fibrosis) were
not identified. These pathologies could contribute to
changes on amikacin pharmacokinetics. The clinical
implementation of improved amikacin dosing regimens
derived from population pharmacokinetic analyses could
have an important contribution to further treatment opti-
mization. However, the IIV that remains even after inclu-
sion of patient-specific predictors is significant and the use
of TDM is likely to remain necessary.
Compliance with Ethical Standards
Funding No sources of funding were used to assist with the prepa-
ration of this review.
Table 6 Amikacin dosing recommendations for neonates suggested by different population pharmacokinetic analyses
Study Population PMA (weeks) PNA (days) cWT (g) Dose (mg/kg) Interval (h) Target
Sherwin et al. [21] Neonates \29 na na 15 36 Cmax: 24–35 mg/L
AUC24: 130–590 mg h/L29–36 14 24
[36 15 24
De Cock et al. [22] Neonates na \14 0–800 16 48 Cmax: 24–35 mg/L
Ctrough: 1.5–3 mg/L800–1200 16 42
1200–2000 15 36
2000–2800 13 30
C 2800 12 24
C 14 0–800 20 42
800–1200 20 36
1200–2000 19 30
2000–2800 18 24
C 2800 17 20
AUC24 area under the concentration–time curve from time zero to 24 h, Cmax maximum (peak) concentration, Ctrough trough concentration, cWT
current body weight, na not applicable, PMA postmenstrual age, PNA postnatal age
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